ITRM(Delisted)
Iterum Therapeutics·NASDAQ
--
--(--)
3.91 / 10
Neutral
Fund‑flow metrics are strong (7.82/10) with positive inflows across all size segments. Analyst coverage is thin: one strong‑buy rating, but historical performance is negative and market sentiment is neutral. Combined with a 79% price drop, outlook remains uncertain.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-05-08
InstitutionHC Wainwright & Co.
Times predicted1
Historical Win Rate0.0%
What is the analyst consensus for ITRM?
- ITRM holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 3.91/10 (Neutral).